Astena Holdings Co.,Ltd. (8095) AI Stock Analysis

• Market Cap: ¥20.70B
• Dividend Yield: 3.52%
• Average Volume (3M): 102.72K
• Price to Earnings (P/E): 8.7
• Beta (1Y): 0.53
• Revenue Growth: 12.75%
• EPS Growth: -191.21%
• Country: JP
• Employees: 1,420
• Sector: Industrials
• Sector Strength: 76
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 19.42
• Shares Outstanding: 41,097,565
• 10 Day Avg. Volume: 105,140
• 30 Day Avg. Volume: 102,720
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥490.00
• Price Target Upside: -3.54% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: ¥490.00 ▼(-3.54% Downside)

The overall score reflects a mix of stable financial health and positive technical indicators, offset by valuation concerns due to negative earnings. The company's strengthening cash flow and operational efficiency are significant positives, while the negative net income and P/E ratio weigh on the valuation.

Astena Holdings Co.,Ltd. Business Overview & Revenue Model

Company Description

Astena Holdings Co., Ltd. (8095) is a Japanese company primarily engaged in the chemicals business. The company operates through several segments including the Chemical Products segment, which focuses on the manufacture and sale of various chemical products, and the Life Science segment, which includes the production and distribution of pharmaceuticals and health-related products. Astena Holdings is known for its innovation in the development of chemical solutions that cater to a wide range of industries, enhancing its reputation as a leader in the chemical sector.

How the Company Makes Money

Astena Holdings Co., Ltd. generates revenue through the sale of chemical products and life science goods. The Chemical Products segment is a major source of income, involving the manufacturing and distribution of industrial chemicals, specialty chemicals, and other related products. The Life Science segment contributes to revenue by providing pharmaceuticals, health supplements, and other life science products. The company leverages its extensive research and development capabilities to create innovative solutions that meet the diverse needs of its clients, thereby driving sales. Strategic partnerships and collaborations in the pharmaceutical and chemicals sectors further bolster its market position and revenue streams.

Astena Holdings Co.,Ltd. Financial Statement Overview

Summary

Astena Holdings shows moderate revenue growth and improved operational efficiency, but negative net income impacts profitability. The balance sheet is stable with reasonable leverage and a solid equity base. Improved cash flow is a positive sign for future growth.

Income Statement

Astena Holdings has shown moderate revenue growth with a 11.55% increase from 2023 to 2024. However, the company is experiencing negative net income, resulting in a net profit margin of -4.35% for 2024. The gross profit margin stands at 33.41%, indicating good operational efficiency. The EBIT margin improved to 4.86% in 2024, showing better cost management compared to previous years.

Balance Sheet

The company's debt-to-equity ratio is 0.59, reflecting a balanced leverage position. The equity ratio is 38.97%, indicating a solid equity base relative to assets. However, the decrease in stockholders' equity over the years suggests potential risks in maintaining financial stability.

Cash Flow

The free cash flow has improved significantly, moving from negative in previous years to a positive 1.65 billion yen in 2024, with a strong free cash flow growth rate. The operating cash flow to net income ratio is high, showcasing effective cash conversion despite losses in net income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	57.99B	51.98B	49.64B	72.32B	65.34B
Gross Profit	19.37B	16.32B	15.44B	16.60B	14.48B
EBITDA	1.14B	4.17B	3.90B	5.21B	4.27B
Net Income	-2.53B	1.16B	579.60M	1.74B	1.98B
Balance Sheet
Total Assets	64.60B	67.25B	63.55B	63.55B	54.32B
Cash, Cash Equivalents and Short-Term Investments	6.10B	6.88B	6.93B	10.93B	7.57B
Total Debt	14.94B	16.91B	15.02B	15.13B	12.17B
Total Liabilities	39.29B	38.65B	36.48B	36.55B	32.67B
Stockholders Equity	25.17B	28.42B	26.99B	27.00B	21.65B
Cash Flow
Free Cash Flow	1.65B	-2.52B	-3.77B	-2.14B	2.39B
Operating Cash Flow	4.85B	1.64B	-742.42M	1.35B	4.14B
Investing Cash Flow	-2.94B	-2.83B	-2.22B	-4.38B	-8.25B
Financing Cash Flow	-2.65B	1.08B	-1.09B	6.35B	6.77B

Astena Holdings Co.,Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 508.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8095, the sentiment is Positive. The current price of 508 is above the 20-day moving average (MA) of 505.55, above the 50-day MA of 485.74, and above the 200-day MA of 463.02, indicating a bullish trend. The MACD of 7.98 indicates Positive momentum. The RSI at 59.98 is Neutral, neither overbought nor oversold. The STOCH value of 26.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8095.

Astena Holdings Co.,Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3417	75 Outperform	¥17.38B	6.07		2.09%	3.70%	37.00%
7679	74 Outperform	¥45.78B	10.42		1.21%	6.65%	12.77%
4350	71 Outperform	¥14.55B	12.04		2.51%	5.93%	-36.11%
3544	64 Neutral	¥11.64B	15.20		1.19%	4.87%	62.84%
Sector *	64 Neutral	$10.71B	16.03	7.42%	2.02%	2.57%	-16.39%
2796	62 Neutral	¥5.87B	―		2.80%	16.60%	-19.16%
8095	60 Neutral	¥20.70B	8.67		3.52%	12.75%	-191.21%

Astena Holdings Co.,Ltd. Corporate Events

Astena Holdings to Strengthen Market Position with Ikeda Bussan Acquisition

Astena Holdings Co., Ltd. announced that its subsidiary, IWAKI Co., Ltd., will acquire shares of the Ikeda Bussan Group, making it a consolidated subsidiary. This acquisition aims to create synergies by expanding product lineups and sales channels, enhancing digital transformation, and strengthening the management base, which is expected to bolster Astena’s operations and market positioning.

Astena Holdings Reports Strong Financial Growth in First Half of 2025

Astena Holdings Co., Ltd. reported a significant increase in its financial performance for the six months ending May 31, 2025, with net sales rising by 7.2% and profit attributable to owners increasing by 82.8% compared to the previous year. The company has revised its earnings forecasts upwards, indicating a positive outlook for the fiscal year ending November 30, 2025, which suggests strong operational performance and potential benefits for stakeholders.

Astena Holdings Exceeds H1 Forecasts, Revises Full-Year Profit Outlook Upwards

Astena Holdings Co., Ltd. reported that its actual financial results for the first half of fiscal year 2025 exceeded forecasts, primarily due to cost reductions and optimization in the Fine Chemicals segment. Consequently, the company has revised its full-year profit forecasts upwards, anticipating continued profit growth, which reflects positively on its operational efficiency and market positioning.

Astena Holdings Announces Leadership Changes to Strengthen Strategic Focus

Astena Holdings Co., Ltd. announced changes in leadership roles, with Keitaro Iwaki taking on additional responsibilities in the fine chemicals business, while Hirotoshi Naruse will manage the pharmaceutical business and structural reform efforts. These changes aim to strengthen the company’s strategic focus and operational efficiency, potentially impacting its market positioning and stakeholder interests.

Astena Holdings Revises 2025 Financial Forecasts Upwards

Astena Holdings Co., Ltd. has revised its financial forecasts for the first half and full fiscal year of 2025, anticipating significant profit growth despite stable net sales. This upward revision is driven by strong performance in the Fine Chemicals and Health & Beauty Care segments, along with deferred R&D expenses in the Medical segment, indicating a positive outlook for stakeholders.